Eupraxia Pharmaceuticals reported positive symptom response data from its ongoing Phase 1b/2a RESOLVE trial for EP-104GI in patients with eosinophilic esophagitis (EoE). In Cohorts 7-9, the proportion of patients experiencing moderate to severe odynophagia decreased from 62% at baseline to 25% at weeks 24 and 52 post-treatment. Severe odynophagia was reported by 15% of patients at baseline but by no patients at week 52. Similarly, moderate to severe dysphagia dropped from 77% at baseline to 25% at weeks 24 and 52, with severe cases eliminating entirely post-treatment. The drug demonstrated a favorable safety profile with over 130 patients treated across more than 2,000 injection sites and no serious adverse events reported. Eupraxia anticipates interim data from the Phase 2b placebo-controlled portion of the trial in Q4 2026. This company operates as a clinical-stage biotechnology firm developing locally delivered, extended-release products using its proprietary Diffusphere technology for therapeutic areas with high unmet medical need.

Eupraxia Pharmaceuticals Inc. filed interim financial statements for the three and six months ended June 30, 2026, reporting a net loss of $14.5 million ($0.23 per share) for the quarter and $27.1 million ($0.46 per share) for the period. The company raised approximately $58.6 million in net proceeds from an overnight public offering of common shares and pre-funded warrants completed on February 20, 2026. Cash and short-term investments totaled $133.7 million as of June 30, 2026. Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company developing drug delivery technologies for unmet medical needs.

Eupraxia Pharmaceuticals announced executive leadership changes and an operational restructuring on July 13, 2026. Dr. Jeff Millard joined as Executive Vice President, Technical Operations, effective July 13, 2026, while Dr. Alex Therien assumed leadership of Research & Development. Amanda Malone stepped down as Chief Scientific and Operating Officer on July 10, 2026. The company transitioned its operations from Victoria to a two-hub structure in Vancouver and Seattle to support clinical growth, with the CEO and key clinical, manufacturing, and commercial leadership based in Seattle. Eupraxia Pharmaceuticals is a biotechnology company focused on clinical and commercial development.